June 7, 2020 / 11:47 PM / a month ago

BRIEF-China Health Group Says Xien Tablet & Rivastigmine Hydrogen Tartrate API Approved For GMP Production

June 8 (Reuters) - China Health Group Inc:

* XIEN TABLET & RIVASTIGMINE HYDROGEN TARTRATE API APPROVED FOR GMP PRODUCTION ON JUNE 5

* XIEN TABLET & RIVASTIGMINE HYDROGEN TARTRATE API GRANTED DRUG PRODUCTION APPROVAL BY NMPA Source text bit.ly/2XEPEKU Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below